National Asset Management Inc. Sells 11,852 Shares of Tekla Life Sciences Investors (NYSE:HQL)

view original post

National Asset Management Inc. lowered its position in shares of Tekla Life Sciences Investors (NYSE:HQLGet Rating) by 48.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,616 shares of the company’s stock after selling 11,852 shares during the quarter. National Asset Management Inc.’s holdings in Tekla Life Sciences Investors were worth $209,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of HQL. 180 Wealth Advisors LLC increased its stake in shares of Tekla Life Sciences Investors by 24.2% during the 1st quarter. 180 Wealth Advisors LLC now owns 85,084 shares of the company’s stock worth $1,429,000 after purchasing an additional 16,554 shares during the last quarter. Wedbush Securities Inc. increased its stake in shares of Tekla Life Sciences Investors by 29.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,170 shares of the company’s stock worth $218,000 after purchasing an additional 2,975 shares during the last quarter. Flagship Harbor Advisors LLC increased its stake in shares of Tekla Life Sciences Investors by 1.3% during the 1st quarter. Flagship Harbor Advisors LLC now owns 339,183 shares of the company’s stock worth $5,610,000 after purchasing an additional 4,454 shares during the last quarter. Twelve Points Wealth Management LLC purchased a new stake in shares of Tekla Life Sciences Investors during the 4th quarter worth approximately $289,000. Finally, Carolinas Wealth Consulting LLC increased its stake in shares of Tekla Life Sciences Investors by 20.8% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 3,467 shares of the company’s stock worth $67,000 after purchasing an additional 597 shares during the last quarter. Institutional investors own 20.69% of the company’s stock.

Tekla Life Sciences Investors Stock Performance

Shares of HQL stock opened at $14.92 on Monday. The company has a 50 day moving average of $14.50 and a 200-day moving average of $15.82. Tekla Life Sciences Investors has a 12-month low of $13.03 and a 12-month high of $22.70.

Tekla Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 30th. Stockholders of record on Friday, May 27th were paid a dividend of $0.35 per share. The ex-dividend date of this dividend was Thursday, May 26th. This represents a $1.40 annualized dividend and a dividend yield of 9.38%.

Tekla Life Sciences Investors Company Profile

(Get Rating)

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

Recommended Stories

Want to see what other hedge funds are holding HQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tekla Life Sciences Investors (NYSE:HQLGet Rating).

Receive News & Ratings for Tekla Life Sciences Investors Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tekla Life Sciences Investors and related companies with MarketBeat.com’s FREE daily email newsletter.